Population-based assessment of determining predictors for quality of prostate cancer surveillance

Cancer

Volumn 121, Issue 23, 2015, Pages 4150-4157

  Chamie, Karim ^a   Williams, Stephen B ^b   Hershman, Dawn L ^c   Wright, Jason D ^c   Nguyen, Paul L ^d   Hu, Jim C ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

prostate cancer; quality; surveillance; treatments; use

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE; AGED; ARTICLE; CANCER DIAGNOSIS; CONSULTATION; FOLLOW UP; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PATIENT MONITORING; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER ACTIVE SURVEILLANCE; VERY ELDERLY; WATCHFUL WAITING; CANCER REGISTRY; COMPARATIVE STUDY; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA; UNITED STATES;

AGED; AGED, 80 AND OVER; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEER PROGRAM; UNITED STATES; WATCHFUL WAITING;

EID: 84948571227     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29574     Document Type: Article

References (30)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29.
2. Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007;69:1095-1101.
3. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009; 302:1202-1209.
4. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68-80.
5. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981-990.
6. Jang TL, Yossepowitch O, Bianco FJ, Jr, Scardino PT. Low risk prostate cancer in men under age 65: the case for definitive treatment. Urol Oncol. 2007;25:510-514.
7. Pickles T, Ruether JD, Weir L, Carlson L, Jakulj F. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int. 2007;100:544-551.
8. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-Derm follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126-131.
9. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol. 2002;167:1231-1234.
10. van As NJ, Norman AR, Thomas K, et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol. 2008;54:1297-1305.
11. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014; 370:932-942.
12. Hayes JH, Ollendorf DA, Pearson SD, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010;304:2373-2380.
13. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005;23:8146-8151.
14. Chamie K, Saigal CS, Lai J, et al. Quality of care in patients with bladder cancer: a case report? Cancer. 2012;118:1412-1421.
15. Simonato A, Varca V, Gacci M, et al. Adherence to guidelines among Italian urologists on imaging preoperative staging of low-risk prostate cancer: results from the MIRROR (Multicenter Italian Report on Radical Prostatectomy Outcomes and Research) study [serial online]. Adv Urol 2012:651061, 2012.
16. Hernes E, Kyrdalen A, Kvale R, et al. Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry. BJU Int. 2010;105:805-811; discussion 811.
17. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 suppl):IV-3-IV-18.
18. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEERMedicare database applications and limitations. Med Care. 2002; 40(8 suppl):IV-19-IV-25.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
20. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267.
21. Loeb S, Berglund A, Stattin P. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol. 2013;190:1742-1749.
22. Williams SB, Salami S, Regan MM, et al. Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial. Cancer. 2012;118:2651-2658.
23. Moyer VA. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157: 120-134.
24. Kapoor DA, Klimberg IW, Malek GH, et al. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology. 1998;52:552-558.
25. Feliciano J, Teper E, Ferrandino M, et al. The incidence of fluoroquinolone resistant infections after prostate biopsy-Are fluoroquinolones still effective prophylaxis? J Urol 2008;179:952-955; discussion 955.
26. Ekwueme DU, Stroud LA, Chen Y. Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies [serial online]. Prev Chronic Dis. 2007;4:A100.
27. Prasad SM, Gu X, Lipsitz SR, Nguyen PL, Hu JC. Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States. Cancer. 2012;118:1260-1267.
28. Cooperberg MR, Lubeck DP, Grossfeld GD, Mehta SS, Carroll PR. Contemporary trends in imaging test utilization for prostate cancer staging: data from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol. 2002;168:491-495.
29. Curfman GD, Morrissey S, Drazen JM. High-value health care-A sustainable proposition [published online ahead of print September 17, 2013]. N Engl J Med. 2013.
30. Daskivich TJ, Kwan L, Dash A, Saigal C, Litwin MS. An ageadjusted comorbidity index for prediction of long-Derm, other-cause mortality in men with prostate cancer. J Urol. 2015;194:73-78.